Predicted structure of agonist-bound glucagon-like peptide 1 receptor, a class B G protein-coupled receptor.
Proc Natl Acad Sci U S A · 2012
Last updated 2026-05-28Researchers predicted the 3D structure of the GLP-1 receptor (GLP1R) when bound to the diabetes drug Exendin-4 (Exe4) using computer modeling. They found 14 strong polar interactions and 10 important hydrophobic interactions between Exe4 and GLP1R, with some of these interactions confirmed by lab tests. The predicted structure matches existing experimental data and could help guide the design of new drugs targeting this receptor.
AI summary of the abstract below.
| Journal | Proc Natl Acad Sci U S A, 2012 |
|---|---|
| Citations | 46 |
| Relative citation ratio | 1.38 |
| NIH percentile | 62 |
| Molecules | — |
Abstract
The glucagon-like peptide 1 receptor (GLP1R) is a G protein-coupled receptor (GPCR) involved in insulin synthesis and regulation; therefore, it is an important drug target for treatment of diabetes. However, GLP1R is a member of the class B1 family of GPCRs for which there are no experimental structures. To provide a structural basis for drug design and to probe class B GPCR activation, we predicted the transmembrane (TM) bundle structure of GLP1R bound to the peptide Exendin-4 (Exe4; a GLP1R agonist on the market for treating diabetes) using the MembStruk method for scanning TM bundle conformations. We used protein-protein docking methods to combine the TM bundle with the X-ray crystal structure of the 143-aa N terminus coupled to the Exe4 peptide. This complex was subjected to 28 ns of full-solvent, full-lipid molecular dynamics. We find 14 strong polar interactions of Exe4 with GLP1R, of which 8 interactions are in the TM bundle (2 interactions confirmed by mutation studies) and 6 interactions involve the N terminus (3 interactions found in the crystal structure). We also find 10 important hydrophobic interactions, of which 4 interactions are in the TM bundle (2 interactions confirmed by mutation studies) and 6 interactions are in the N terminus (6 interactions present in the crystal structure). Thus, our predicted structure agrees with available mutagenesis studies. We suggest a number of mutation experiments to further validate our predicted structure. The structure should be useful for guiding drug design and can provide a structural basis for understanding ligand binding and receptor activation of GLP1R and other class B1 GPCRs.
Verbatim abstract via PubMed 23169631 ↗